Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort-Reference-Cited by-同舟云学术

Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort

Published:2022-02-22 Issue:1 Volume:7 Page:
ISSN:2379-5077
Container-title:mSystems
language:en
Short-container-title:mSystems

Author:

Yıldırım Süleyman¹²^ORCID,Nalbantoğlu Özkan Ufuk³⁴,Bayraktar Abdulahad⁵,Ercan Fatma Betül⁶,Gündoğdu Aycan⁴⁷,Velioğlu Halil Aziz²⁶,Göl Mehmet Fatih⁷,Soylu Ayten Ekinci⁷,Koç Fatma¹,Gülpınar Ezgi Aslan⁷,Kadak Kübra Sogukkanlı⁶,Arıkan Muzaffer²,Mardinoğlu Adil⁵⁸,Koçak Mehmet⁹,Köseoğlu Emel¹⁰,Hanoğlu Lütfü¹¹

Affiliation:

1. Department of Medical Microbiology, Istanbul Medipol University International School of Medicine, Istanbul, Turkey

2. Regenerative and Restorative Medicine Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul, Turkey

3. Department of Computer Engineering, Erciyes University, Kayseri, Turkey

4. Genome and Stem Cell Center (GenKok), Erciyes University, Kayseri, Turkey

5. Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, United Kingdom

6. Graduate Program in Neuroscience, Istanbul Medipol University International School of Medicine, Istanbul, Turkey

7. Department of Microbiology and Clinical Microbiology, Erciyes University School of Medicine, Kayseri, Turkey

8. Science for Life Laboratory, KTH—Royal Institute of Technology, Stockholm, Sweden

9. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA

10. Department of Neurology, School of Medicine, Erciyes University, Kayseri, Turkey

11. Department of Neurology, School of Medicine, Istanbul Medipol University, Istanbul, Turkey

Abstract

The prevalence of AD worldwide is estimated to reach 131 million by 2050. Most disease-modifying treatments and drug trials have failed, due partly to the heterogeneous and complex nature of the disease.

Funder

Türkiye Bilimsel ve Teknolojik Araştirma Kurumu

Publisher

American Society for Microbiology

Subject

Computer Science Applications,Genetics,Molecular Biology,Modeling and Simulation,Ecology, Evolution, Behavior and Systematics,Biochemistry,Physiology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/msystems.00004-22

Reference81 articles.

1. Alzheimer’s Disease International. 2015. World Alzheimer Report 2015: the global impact of dementia. An analysis of prevalence incidence cost and trends. https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf. Accessed 20 September 2020.

2. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

3. On the path to 2025: understanding the Alzheimer’s disease continuum

4. A review on Alzheimer's disease pathophysiology and its management: an update

5. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of human gut microbiome on the healthy and the neurodegenerative aging;Experimental Gerontology;2024-09

2. Therapeutic Potential of Fungal Polysaccharides in Gut Microbiota Regulation: Implications for Diabetes, Neurodegeneration, and Oncology;Journal of Fungi;2024-05-31

3. Distinct gut microbiota profiles may characterize amyloid beta pathology and mild cognitive impairment;2024-05-03

4. Psychobiotics and the Microbiota–Gut–Brain Axis: Where Do We Go from Here?;Microorganisms;2024-03-22

5. The Role of Diet and Gut Microbiota in Alzheimer’s Disease;Nutrients;2024-01-31